Efficacy of the New Neuraminidase Inhibitor CS-8958 against H5N1 Influenza Viruses

Currently, two neuraminidase (NA) inhibitors, oseltamivir and zanamivir, which must be administrated twice daily for 5 days for maximum therapeutic effect, are licensed for the treatment of influenza. However, oseltamivir-resistant mutants of seasonal H1N1 and highly pathogenic H5N1 avian influenza A viruses have emerged. Therefore, alternative antiviral agents are needed. Recently, a new neuraminidase inhibitor, R-125489, and its prodrug, CS-8958, have been developed. CS-8958 functions as a long-acting NA inhibitor in vivo (mice) and is efficacious against seasonal influenza strains following a single intranasal dose. Here, we tested the efficacy of this compound against H5N1 influenza viruses, which have spread across several continents and caused epidemics with high morbidity and mortality. We demonstrated that R-125489 interferes with the NA activity of H5N1 viruses, including oseltamivir-resistant and different clade strains. A single dose of CS-8958 (1,500 µg/kg) given to mice 2 h post-infection with H5N1 influenza viruses produced a higher survival rate than did continuous five-day administration of oseltamivir (50 mg/kg twice daily). Virus titers in lungs and brain were substantially lower in infected mice treated with a single dose of CS-8958 than in those treated with the five-day course of oseltamivir. CS-8958 was also highly efficacious against highly pathogenic H5N1 influenza virus and oseltamivir-resistant variants. A single dose of CS-8958 given seven days prior to virus infection also protected mice against H5N1 virus lethal infection. To evaluate the improved efficacy of CS-8958 over oseltamivir, the binding stability of R-125489 to various subtypes of influenza virus was assessed and compared with that of other NA inhibitors. We found that R-125489 bound to NA more tightly than did any other NA inhibitor tested. Our results indicate that CS-8958 is highly effective for the treatment and prophylaxis of infection with H5N1 influenza viruses, including oseltamivir-resistant mutants.

[1]  L. Simonsen.  The global impact of influenza on morbidity and mortality. , 1999, Vaccine.

[2]  Tokiko Watanabe,et al.  Generation of influenza A viruses entirely from cloned cDNAs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[3]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[4]  P. Horby,et al.  Influenza A H5N1 Clade 2.3.4 Virus with a Different Antiviral Susceptibility Profile Replaced Clade 1 Virus in Humans in Northern Vietnam , 2008, PloS one.

[5]  Takanori Tomozawa,et al.  CS-8958, a Prodrug of the New Neuraminidase Inhibitor R-125489, Shows Long-Acting Anti-Influenza Virus Activity , 2008, Antimicrobial Agents and Chemotherapy.

[6]  Larisa V. Gubareva,et al.  Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants , 2001, Antimicrobial Agents and Chemotherapy.

[7]  M. Peiris,et al.  Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus , 1998, The Lancet.

[8]  R. Webster,et al.  Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. , 2005, The Journal of infectious diseases.

[9]  Keiji Fukuda,et al.  Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2002, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[10]  Satoru Kaneko,et al.  Synthesis and anti-influenza virus activity of 7-O-alkylated derivatives related to zanamivir. , 2002, Bioorganic & medicinal chemistry letters.

[11]  T. B. Usman,et al.  Reduced sensitivity of influenza A (H5N1) to oseltamivir. , 2007, Emerging infectious diseases.

[12]  Xiyan Xu,et al.  Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern , 2005, The Lancet.

[13]  Yoshiyuki Kobayashi,et al.  Synthesis and anti-influenza virus activity of 4-guanidino-7-substituted Neu5Ac2en derivatives. , 2002, Bioorganic & medicinal chemistry letters.

[14]  Hideo Goto,et al.  Avian flu: Isolation of drug-resistant H5N1 virus , 2005, Nature.

[15]  S. Bantia,et al.  Anti-influenza virus activity of peramivir in mice with single intramuscular injection. , 2006, Antiviral research.

[16]  Malbea A Lapete,et al.  Prevention and Control of Influenza Recommendations of the Advisory Committee on Immunization Practices ( ACIP ) , 2004 .

[17]  Yoshihiro Kawaoka,et al.  oseltamivir: descriptive study , 2022 .

[18]  J. Montgomery,et al.  Comparison of the Anti-Influenza Virus Activity of RWJ-270201 with Those of Oseltamivir and Zanamivir , 2001, Antimicrobial Agents and Chemotherapy.

[19]  L. Finelli,et al.  Emergence of a novel swine-origin influenza A (H1N1) virus in humans. , 2009, The New England journal of medicine.

[20]  Oseltamivir-Resistant Influenza A Viruses Circulating in Japan , 2009, Journal of Clinical Microbiology.

[21]  M. Paulshock,et al.  Antiviral Activity of 1-Adamantanamine (Amantadine) , 1964, Science.

[22]  Yi Guan,et al.  Oseltamivir resistance during treatment of influenza A (H5N1) infection. , 2005, The New England journal of medicine.

[23]  N. Cox,et al.  Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. , 1998, Science.

[24]  Jin Hyun Kim,et al.  Growth of H5N1 Influenza A Viruses in the Upper Respiratory Tracts of Mice , 2007, PLoS pathogens.

[25]  Hideo Goto,et al.  In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses , 2009, Nature.

[26]  M. Kiso,et al.  Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. , 2007, JAMA.

[27]  D. Smee,et al.  Cyclopentane Neuraminidase Inhibitors with Potent In Vitro Anti-Influenza Virus Activities , 2001, Antimicrobial Agents and Chemotherapy.

[28]  C. Macken,et al.  Phylogenetic characterization of H5N1 avian influenza viruses isolated in Indonesia from 2003-2007. , 2009, Virology.

[29]  C. Gerdil.  The annual production cycle for influenza vaccine. , 2003, Vaccine.

[30]  T. Uyeki,et al.  Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. , 2008, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[31]  P. Ward,et al.  Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. , 2005, The Journal of antimicrobial chemotherapy.

[32]  A. Nicoll,et al.  Observed oseltamivir resistance in seasonal influenza viruses in Europe interpretation and potential implications. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[33]  Keiji Fukuda,et al.  WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus , 2006, The Lancet Infectious Diseases.

[34]  N. Cox,et al.  Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. , 2006, JAMA.

[35]  Gabriele Neumann,et al.  Emergence and pandemic potential of swine-origin H1N1 influenza virus , 2009, Nature.

[36]  A J Elliott,et al.  BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. , 2000, Journal of medicinal chemistry.

[37]  Gavin J. D. Smith,et al.  Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. , 2006, The Journal of infectious diseases.

[38]  R. Webster,et al.  Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus , 1998, The Lancet.

[39]  F. Hayden,et al.  Perspectives on antiviral use during pandemic influenza. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.